MarketCap
Facebook
X
Telegram
Leap Therapeutics Balance Sheet 2025-2011 | LPTX
Brief overview of Leap Therapeutics's balance sheet strength
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets increased from $117.9 million to $163.2 million, or +38.4%; CAGR of about 8.5% indicates steady balance sheet expansion.
Growth in the asset base was not matched by liabilities: +38.4% versus -3.5%. The balance sheet moved in a more conservative direction.
Equity funds 94.1% of assets versus 91.5% initially. This creates a conservative balance sheet structure.
The cash share moved from 97.5% to 8.6%. A higher figure generally provides more room in an adverse scenario.
The balance sheet carries negative retained earnings of -$462.5 million. The figure may result from accumulated losses or an active capital return policy.
Overall picture
Leap Therapeutics's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet Leap Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -64.8 M | -114 M | -51.5 M | -2.86 M | -16.3 M | -25.7 M | 29.5 M | -21 M | -10.9 M | -19 M | -15.3 M | - |
Long Term Debt |
- | - | - | 262 K | 37 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
38 K | 266 K | 262 K | 416 K | 432 K | 408 K | 474 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 348 K | 711 K | 3.45 M | 11.9 M | 70.5 M | - | - | - | 3.11 M | - |
Total Current Liabilities |
4.56 M | 14.1 M | 12.7 M | 11.2 M | 9.99 M | 7.37 M | 8.49 M | 6.45 M | 6.08 M | - | - | - | - | - | - |
Total Liabilities |
9.68 M | 14.1 M | 12.7 M | 11.5 M | 10 M | 7.72 M | 9.2 M | 9.9 M | 17.9 M | 6.46 M | 1.28 M | 2.49 M | 1.97 M | 4.61 M | - |
Deferred Revenue |
- | - | - | - | - | 1.5 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-463 M | -467 M | -400 M | -318 M | -264 M | -223 M | -195 M | -154 M | -130 M | -101 M | -89.3 M | -68.2 M | -42.7 M | -24.4 M | - |
Total Assets |
163 M | 49.1 M | 72.8 M | 70.4 M | 118 M | 54.4 M | 7.45 M | 19.1 M | 29.1 M | 6.46 M | 28.1 M | 48.7 M | 20.7 M | 17.7 M | - |
Cash and Cash Equivalents |
14 M | 47.2 M | 70.6 M | 65.5 M | 115 M | 52.1 M | 3.89 M | 16.3 M | 25.7 M | - | - | - | - | - | - |
Book Value |
154 M | 35 M | 60.1 M | 58.9 M | 108 M | 46.7 M | -1.75 M | 9.18 M | 11.1 M | - | 26.9 M | 46.2 M | 18.8 M | 13.1 M | - |
Total Shareholders Equity |
154 M | 35 M | 60.1 M | 58.9 M | 108 M | 46.7 M | -1.75 M | 9.18 M | 11.1 M | -100 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Leap Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | 39 K | 154 K | - | - | 38 K | 152 K | 262 K | 369 K | 474 K | - | 37 K | - | - | 36 K | 144 K | 144 K | 144 K | 144 K | 552 K | 552 K | 552 K | 552 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
9.68 M | 3 M | 14.1 M | 8.7 M | - | - | 14.1 M | 16.1 M | 15.6 M | 10.6 M | 12.7 M | 11 M | 11.8 M | 10.5 M | 11.5 M | 12.1 M | 10.9 M | 7.34 M | 10 M | 11.3 M | 8.06 M | 7.43 M | 7.72 M | 7.72 M | 7.72 M | 7.72 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 36.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 375 K | 750 K | 1.12 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-463 M | -540 M | -467 M | -503 M | -499 M | -483 M | -467 M | -452 M | -434 M | -413 M | -400 M | -387 M | -373 M | -360 M | -318 M | -306 M | -291 M | -274 M | -264 M | -253 M | -242 M | -232 M | -223 M | -223 M | -223 M | -223 M | -195 M | -195 M | -195 M | -195 M | -154 M | -154 M | -154 M | -154 M | -130 M | -130 M | -130 M | -130 M | -101 M | -101 M | -101 M | -101 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
163 M | 87.4 M | 49.1 M | 11.4 M | 20 M | 34.9 M | 49.1 M | 65 M | 81.4 M | 58 M | 72.8 M | 83 M | 95.9 M | 107 M | 70.4 M | 82.2 M | 94.2 M | 106 M | 118 M | 128 M | 37.9 M | 45.8 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 7.45 M | 7.45 M | 7.45 M | 7.45 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 29.1 M | 29.1 M | 29.1 M | 29.1 M | 6.46 M | 6.46 M | 6.46 M | 6.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
47.2 M | 6.69 M | 70.6 M | 9.69 M | 18.1 M | 32.7 M | 47.2 M | 62.8 M | 78.5 M | 54.9 M | 70.6 M | 80.7 M | 91.4 M | 102 M | 65.5 M | 78.3 M | 90.9 M | 103 M | 115 M | 125 M | 35.7 M | 43.5 M | 52.1 M | 52.1 M | 52.1 M | 52.1 M | 3.89 M | 3.89 M | 3.89 M | 3.89 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 25.7 M | 25.7 M | 25.7 M | 25.7 M | 793 K | 793 K | 793 K | 793 K | 405 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
154 M | 84.4 M | 35 M | 2.7 M | - | - | 35 M | 49 M | 65.8 M | 47.4 M | 60.1 M | 72 M | 84.1 M | 96 M | 58.9 M | 70.1 M | 83.3 M | 98.6 M | 108 M | 117 M | 29.9 M | 38.4 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | -1.75 M | -1.75 M | -1.75 M | -1.75 M | 9.18 M | 9.18 M | 9.18 M | 9.18 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | -29.7 M | 6.46 M | 6.46 M | 6.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
35 M | 84.4 M | 60.1 M | 2.7 M | 5.72 M | 20.8 M | 35 M | 49 M | 65.8 M | 47.4 M | 60.1 M | 72 M | 84.1 M | 28.3 M | 58.9 M | 70.1 M | 83.3 M | 98.6 M | 108 M | 117 M | 29.9 M | 38.4 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | -1.75 M | -1.75 M | -1.75 M | -1.75 M | 9.18 M | 9.18 M | 9.18 M | 9.18 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | -100 M | -100 M | -100 M | -100 M | -70.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Leap Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
